Lycera Expands Partnership with Merck for Potential $600M
Lycera Corp. doubled its sweet 2011 deal with Merck and Co. Inc., of Whitehouse Station, N.J., in a new agreement designed to expand on the companies' prior relationship, which has centered on retinoic acid-related orphan receptor (ROR[gamma]t). Lycera will receive an undisclosed up-front payment and research funding, and could receive more than $300 million in milestone payments based on research, development, regulatory and commercial accomplishments, plus royalties on marketed products.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter